Eric Lefebvre - 09 Jul 2024 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Reporting relationship: Chief Medical Officer
Issuer ticker: PLRX
Reported as of: 09 Jul 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Jul 2024, 17:01:03 UTC
Prior SEC filing: 22 Mar 2024
Next SEC filing: 12 Jul 2024
Source filing: View source filing
Reporting owner signature: /s/ Mike Ouimette, attorney-in-fact

Key filing fact

Eric Lefebvre filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 11 Jul 2024.

Key facts

This page summarizes Eric Lefebvre's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Jul 2024, 17:01.

Change

Previous filing in this sequence was filed on 22 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PLRX transaction

Common Stock

Award

Transaction value: $0
Shares: +24,063
Change %: +12%
Price: $0.000000
Shares after: 225,371
Date: 09 Jul 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On July 28, 2022, the Reporting Person was granted 87,500 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 24,063 shares.

Footnote F2

Includes 1,488 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program.